Glucocorticoid-induced osteoporosis: pathophysiology and therapy.
about
Management issues with exogenous steroid therapyTreatment of Cushing disease: overview and recent findingsACTH protects against glucocorticoid-induced osteonecrosis of boneMetabolic consequences of modern immunosuppressive agents in solid organ transplantationRisk factors for osteoporosis in inflammatory bowel disease patientsGlucocorticoid-induced osteoporosisParathyroid hormone pulsatility: physiological and clinical aspectsMechanism and Treatment Strategy of Osteoporosis after TransplantationGlucocorticoid-induced osteoporosis in children with 21-hydroxylase deficiencyBisphosphonate therapy in pediatric patientsManagement of endocrine disease: Secondary osteoporosis: pathophysiology and managementMultiscale alterations in bone matrix quality increased fragility in steroid induced osteoporosisMetabolomics and Its Application in the Development of Discovering Biomarkers for Osteoporosis ResearchDisorders of bone remodelingMind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures.Physical inactivity: a risk factor and target for intervention in renal care.Epidemiology of Fractures in Diabetes.The management of osteoporosis in children.Vitamin D—update for the pediatric rheumatologistsManagement of glucocorticoid-induced osteoporosis: clinical data in relation to disease demographics, bone mineral density and fracture risk.Bone mass and biochemical markers of bone turnover in children and adolescents with chronic immune thrombocytopenia: relation to corticosteroid therapy and vitamin D receptor gene polymorphisms.Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies.Osteoporosis prophylaxis in patients receiving chronic glucocorticoid therapySclerostin activity plays a key role in the negative effect of glucocorticoid signaling on osteoblast function in mice.Glucocorticoids, osteocytes, and skeletal fragility: the role of bone vascularity.Extracellular matrix molecules: potential targets in pharmacotherapy.Update in new anabolic therapies for osteoporosisSkeletal findings in the first 12 months following initiation of glucocorticoid therapy for pediatric nephrotic syndromeA rational use of glucocorticoids in patients with early arthritis has a minimal impact on bone mass.Influence of glucocorticoids on the osteogenic differentiation of rat bone marrow-derived mesenchymal stem cells.The use of glucocorticoids in rheumatoid arthritis--no 'rational' approach yetPrevalence and correlates of osteoporosis in chronic obstructive pulmonary disease patients in IndiaChallenges in implementing and maintaining osteoporosis therapy.Col3.6-HSD2 transgenic mice: a glucocorticoid loss-of-function model spanning early and late osteoblast differentiation.A review of lifestyle, smoking and other modifiable risk factors for osteoporotic fractures.Osteoporosis and gastrointestinal disease.Relationship between use of antidepressants and risk of fractures: a meta-analysis.Increased marrow adiposity in premenopausal women with idiopathic osteoporosisImpaired bone health in inflammatory bowel disease: a case-control study in 80 pediatric patients.An N-ethyl-N-nitrosourea induced corticotropin-releasing hormone promoter mutation provides a mouse model for endogenous glucocorticoid excess
P2860
Q24564449-221B027F-880C-4E6F-ADEA-CE5FAE7186F2Q24626819-0D64CE1D-4A00-4CB8-98A2-19687A1D73E3Q24631407-E4C6EF70-7541-4AFB-A754-BAA3F93F61BEQ26746936-C8F1AB70-0443-4D32-9850-FE59024A1A68Q26776142-4F6F6A2E-A4AE-4289-9E35-881331552DA9Q26778272-3A00B14B-7E4D-4D8D-B213-A192CE76839BQ26798180-616A9D53-723B-4580-B710-269C1385F282Q26798296-9A56C10F-6124-407B-B10E-F3060C1F6333Q26821908-0593AF37-C7F9-431D-8CAD-FDC6D55C288EQ26830702-DAEB1E02-7333-447D-9EED-A03E7581DB22Q26998249-80810587-A891-4382-8DAD-B88A45357489Q27324822-428E2218-9CBD-45CE-8C65-40D41560CF04Q28068862-6C00C3C0-48BA-4A8E-AEEC-57F41EED09A1Q28295303-99697AA5-CE61-4D12-B196-0735C3EE207DQ30236007-1A2C57D6-60AD-4354-990D-E8366F483213Q30238711-BA77D9C2-CB79-49B3-8A75-D2542BEF178EQ30248863-5223E40F-5071-4339-B068-23F1082AABBCQ30251490-ED1F11A9-577C-487F-8782-4EEEC7AA5F8AQ30375070-C9AD2F80-E4EA-4EC7-9911-6F186C7D260DQ30946308-A7B6EA0E-328B-4382-B8F1-0441F9CE5BBEQ33401642-60A8F702-53D2-4217-A1C0-E2D3865FD14BQ33505798-D2D9D58F-6AB6-4E5B-AE61-FA4D57962028Q33619648-BFCA27F2-D2E2-4158-B99F-3832F872577DQ33651412-ADB4ADE3-D779-49FC-96FA-618D50C32BC2Q33665237-176E444B-ED49-4C58-AE1E-661D79EB9586Q33694487-B8B8505A-639C-4F12-B98E-B9854C5D65BEQ33786824-BF0C3D3F-71AA-46DE-B4DE-EA7663B12176Q33911068-9A35AD8C-35D2-4FFE-AF5D-25A9CF213BA6Q33923332-4F553010-034E-4900-9ADD-41417D4C0A3DQ33942172-539DB7AC-357A-4657-A560-C568301C3FB3Q34027540-716C6C02-52BC-4A11-86E8-A6CF49EA41D6Q34031486-8509DC38-B2AA-4C30-8910-0F9B0F0B3428Q34073740-4470A927-EAC6-40AA-AD45-4FDFA6E69AEAQ34079475-DC84BD9C-959E-499C-AC4E-53F5AC222575Q34171853-46737AAB-8A02-4744-80F5-BD9D8DCED015Q34178759-53B1E9BB-421E-47EC-BD37-08E219F245A6Q34277620-524E76F6-1047-428E-8A69-2B5A2CC6E8E5Q34281779-549CB15E-22E0-441D-89E0-48BC042A47EFQ34316049-26CC7ACB-3481-4042-A919-73D5D6EC538AQ34316496-A2953284-2FEA-4CFF-9AAA-F1A21069E5C2
P2860
Glucocorticoid-induced osteoporosis: pathophysiology and therapy.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Glucocorticoid-induced osteoporosis: pathophysiology and therapy.
@en
type
label
Glucocorticoid-induced osteoporosis: pathophysiology and therapy.
@en
prefLabel
Glucocorticoid-induced osteoporosis: pathophysiology and therapy.
@en
P2093
P1476
Glucocorticoid-induced osteoporosis: pathophysiology and therapy.
@en
P2093
A Giustina
G Mazziotti
J P Bilezikian
P2888
P304
P356
10.1007/S00198-007-0394-0
P407
P577
2007-06-14T00:00:00Z